Evidence map›Paper›PMID 33999486›Full record

Trial reportEuropean journal of heart failure2021

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.

Adriaan A Voors, Hillary Mulder, Eugene Reyes, Martin R Cowie, Johan Lassus, Adrian F Hernandez, Justin A Ezekowitz, Javed Butler, Christopher M O'Connor, Joerg Koglin and 7 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Efficacy and safety of vericiguat in heart failure: a meta-analysis.The Journal of international medical research · 2023
    Pooled it
  4. Pooled it
  5. Right Heart Function in Cardiorenal Syndrome.Current heart failure reports · 2022
    Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Adriaan A VoorsUniversity of Groningen, Groningen, The Netherlands.
Hillary MulderDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Eugene ReyesUniversity of the Philippines, College of Medicine, Manila, Philippines.
Martin R CowieRoyal Brompton Hospital & School of Cardiovascular Medicine & Sciences, Faculty of Life Sciences & Medicine, King's College London, London, UK.
Johan LassusHelsinki University Central Hospital, Helsinki, Finland.
Adrian F HernandezDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Justin A EzekowitzCanadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
Javed ButlerUniversity of Mississippi Medical Center, Jackson, MS, USA.
Christopher M O'ConnorInova Heart and Vascular Institute, Falls Church, VA, USA.
Joerg KoglinMerck & Co. Inc., Kenilworth, NJ, USA.
Carolyn S P LamNational Heart Centre Singapore & Duke-National University of Singapore, Singapore.
Burkert PieskeCharité University Medicine, German Heart Center, Berlin, Germany.
Lothar RoessigBayer AG, Wuppertal, Germany.
Piotr PonikowskiWroclaw Medical University, Wroclaw, Poland.
Kevin J AnstromDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
Paul W ArmstrongCanadian VIGOUR Centre, University of Alberta, Edmonton, Canada.
VICTORIA Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsVericiguat reduced the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization in patients with worsening HF with reduced ejection fraction (HFrEF) and a lower limit of baseline estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m METHODS AND

resultsIn VICTORIA, core laboratory serum creatinine was measured at baseline (n = 4956) and weeks 16, 32, and 48. Worsening renal function (WRF), defined as an increase ≥0.3 mg/dL in creatinine from baseline to week 16, was assessed via a Cox model with respect to subsequent primary events. Mean age was 69 years, 24% were female, and mean baseline eGFR was 61 mL/min/1.73 m

conclusionRenal function trajectories were similar between vericiguat- and placebo-treated patients and the beneficial effects of vericiguat on the primary outcome were consistent across the full range of eGFR and irrespective of WRF.

Indexed as

Heart FailureAgedFemaleGlomerular Filtration RateHeterocyclic Compounds, 2-RingHumansKidneyMalePyrimidinesStroke VolumeTreatment OutcomeHeterocyclic Compounds, 2-RingPyrimidinesvericiguatEstimated glomerular filtration rateHeart failureHeart failure with reduced ejection fractionRenal function

Identifiers

PMID33999486
PMCPMC8453520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.